It is also indicated for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
It is also indicated for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
ZUMA-3 is an ongoing international single-arm, open-label, registrational phase I/II study of Tecartus in adult patients (≥18 years old) with ALL whose disease is refractory to or has relapsed following standard systemic therapy or hematopoietic stem cell transplantation. The primary endpoint is the rate
of overall complete remission (CR) or complete remission with incomplete hematological recovery by central assessment. The secondary endpoints are duration of remission and relapse-free survival, overall survival, minimal residual disease (MRD) negativity rate and alloSCT rate.
The three-year follow-up results showed a median overall survival (OS) of 26 months and demonstrated that responses remained durable in adults with relapsed/refractory B-cell ALL, with a consistent safety profile observed since the two-year analysis.
Comments
Post a Comment